Duration of dual antiplatelet treatment in the era of next generation drug-eluting stents

Table 3 Two year clinical outcomes of TWENTE trial n (%)

	Resolute ZES	Xience V EES	Difference	P
	(n = 695)	(n = 692)	(95%CI)
Target vessel failure	75 (10.8)	80 (11.6)	-0.8 (-4.1 to 2.6)	0.65
Death
Any cause	29 (4.2)	33 (4.8)	-0.6 (-2.8 to 1.6)	0.59
Cardiac cause	11 (1.6)	19 (2.7)	-1.2 (-2.7 to 0.4)	0.14
Target vessel–related myocardial infarction
Any	37 (5.3)	39 (5.6)	-0.3 (-2.7 to 2.1)	0.80
Q-wave	8 (1.2)	9 (1.3)	-0.2 (-1.3 to 1.0)	0.80
Non–Q-wave	29 (4.2)	30 (4.3)	-0.2 (-2.3 to 2.0)	0.88
Clinically indicated target vessel revascularization
Any	39 (5.6)	35 (5.1)	0.6 (−1.8 to 2.9)	0.65
Target lesion failure	73 (10.5)	68 (9.8)	0.7 (−2.5 to 3.9)	0.68
Clinically indicated target lesion revascularization
Any	34 (4.9)	18 (2.6)	2.3 (0.3 to 4.3)	0.03
Death from cardiac causes or target vessel myocardial infarction	46 (6.6)	53 (7.7)	-1.0 (-3.8 to 1.7)	0.45
Major adverse cardiac events1	90 (12.9)	82 (11.8)	1.1 (-2.4 to 4.6)	0.53
Patient-oriented composite endpoint2	114 (16.4)	118 (17.1)	-0.7 (-4.6 to 3.3)	0.75
Stent thrombosis
Definite (0-720 d)	6 (0.9)	1 (0.1)	0.7 (-0.0 to 1.5)	0.12
Definite or probable (0-720 d)	8 (1.2)	10 (1.4)	-0.3 (-1.5 to 0.9)	0.63
Definite, probable, or possible (0-720 d)	14 (2.0)	20 (2.9)	-0.9 (-2.5 to 0.8)	0.29
Very late definite or probable (361-720 d)	2 (0.3)	2 (0.3)	0 (-0.6 to 0.6)	1.00

Values are n (%).

¹Major adverse cardiac events is a composite of all-cause death, any myocardial infarction, emergent coronary artery bypass surgery and clinically indicated target lesion revascularization;

²Patient-oriented composite endpoint is a composite endpoint of all-cause death, any myocardial infarction and any revascularization. (Modified from Ref. [17]). ZES: Zotarolimus-eluting stent; EES: Everolimus-eluting stent.